Werewolf Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

HOWL$0.97-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations for the and

Condensed Consolidated Statements of Operations (unaudited)

(amounts in thousands, except share and per share amounts)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2025	2024	2025	2024
Revenue:
Collaboration revenue	$—	$—	$—	$1,885
Operating expenses:
Research and development	11,634	12,528	37,897	40,707
General and administrative	4,092	4,596	13,362	14,424
Total operating expenses	15,726	17,124	51,259	55,131
Operating loss	(15,726)	(17,124)	(51,259)	(53,246)
Other (expense) income:
Interest income	697	1,598	2,544	5,364
Interest expense	(1,341)	(1,244)	(3,905)	(3,389)
Loss on extinguishment of debt	—	—	—	(553)
Other income, net	—	97	179	1,709
Total other (expense) income	(644)	451	(1,182)	3,131
Net loss	$(16,370)	$(16,673)	$(52,441)	$(50,115)
Net loss per common share, basic	$(0.36)	$(0.38)	$(1.16)	$(1.17)
Net loss per common share, diluted	$(0.36)	$(0.38)	$(1.16)	$(1.19)
Weighted-average common shares outstanding, basic	45,804,042	43,704,836	45,207,894	42,947,282
Weighted-average common shares outstanding, diluted	45,804,042	43,704,836	45,207,894	43,386,287

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.